echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > The sword refers to the successful phase III clinical trial of Johnson & Johnson's Stelara Amgen biosimilar drug ABP 654!

    The sword refers to the successful phase III clinical trial of Johnson & Johnson's Stelara Amgen biosimilar drug ABP 654!

    • Last Update: 2022-05-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Amgen announced the preliminary results of a Phase 3 clinical study
    .
    This is a multicenter, randomized, double-blind, comparative clinical study (Study ID: 04607980) evaluating the biosimilar ABP 654 versus Stelara (hi Dano, ustekinumab, ustekinumab) efficacy and safety
    .
    A total of 563 patients were enrolled in the study, including 281 in the ABP 654 treatment group and 282 in the Stelara treatment group
    .
    Results showed that the study met its primary efficacy endpoint: no clinically meaningful difference between ABP 654 and Stelara
    .
    This preliminary assessment analyzed percent improvement in the Psoriasis Area and Severity Index (PASI) from baseline to Week 12 of treatment
    .
    The data showed a mean difference in percent improvement in PASI between ABP 654 and Stelara of 0.
    14, which was within a pre-specified cut-off value
    .
    ABP 654 is comparable in security to Stelara
    .
    ABP 654 is currently being developed as a biosimilar to Stelara, which is identical to Stelara in dosage form, dose strength, route of administration and dosing schedule
    .
    Stelara is an old-fashioned anti-inflammatory drug from Johnson & Johnson, which is the world's first biological agent that can selectively target IL-12 and IL-23 at the same time
    .
    IL-12 and IL-23 are two naturally occurring cytokines with key roles in immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative Colitis,
    etc.
    Stelara specifically binds to the p40 subunit shared by IL-12 and IL-23 with high affinity, preventing its binding to cell surface receptors, thereby disrupting IL-12 and IL-23-mediated signaling and cytokine effects
    .
    It is understood that Stelara was launched in 2009 and has been approved for multiple indications, including: (1) Adult and pediatric patients with moderate to severe plaque psoriasis (≥6 years old) suitable for phototherapy or systemic therapy; ( 2) for the treatment of adults with active psoriatic arthritis; (3) for the treatment of adults with moderately to severely active Crohn's disease; (4) for the treatment of adults with moderately to severely active ulcerative colitis
    .
    It is worth noting that Stelara plays a mainstay role in Johnson & Johnson's pharmaceutical business segment
    .
    According to the company's financial report, Stelara's global sales in 2021 will reach US$9.
    134 billion, an increase of 18.
    5% over the previous year, accounting for 28% of its entire pharmaceutical business segment
    .
    However, Stelara's main U.
    S.
    patent will expire in 2023, and several companies are currently developing related biosimilars
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.